Explore the Agenda
Bispecific ADCs Day - 이중특이성 ADC 데이
Uncover key scientific and technical updates in the rapidly evolving area of bispecific ADCs
The agenda will address the drivers behind the innovation, as well as the science behind target selection, conjugation strategies, and the manufacturing of bispecific ADCs. Leave with all the knowledge you might need to develop your own successful and clinically viable Bispecific ADC.
This day is intended for researchers currently developing bispecific ADCs and those seeking to expand or initiate research efforts in this area.
* This day is shared with attendees of the 5th World ADC Summit South Korea
8:00 am Check-In & Morning Coffee
Defining Target Selection for Bispecific ADCs to Ensure Efficacy & Therapeutic Impact
9:00 am From Proximity Mapping to Therapeutics: Rational Target-Pair Selection With the MINTTM Platform for Bispecific ADCs
- Explore how MINT™ maps cell-surface protein microenvironments using proximity proteomics and machine learning to identify novel, co-localized target pairs for precision therapeutics
- Outline how applying MINT™ enables rational selection of tumor-associated proximity antigens (TAPAs), guiding the design of bispecific ADCs with improved tumor selectivity and reduced off-target engagement
- Analyze how this proximity-driven framework supports the discovery and optimization of multiple bispecific ADC candidates, providing a systematic path from target-pair identification to preclinical validation
9:30 am Exploring Improving Penetration of Anti-Cancer Drugs Into TME & Designing Bispecific ADCs
- Exploring PMC-403, a novel TIE2 trans binding vessel normalizer in TME
- Introducing PMC-005 (EGFRviii) and PAb-100 (MUC1) and exploring bispecific ADC
- Discussing a hypothesis of PMC-403 and Bispecific ADC targeting EGFRviii and MUC1
10:00 am Morning Break
10:45 am Networking Session
Network with fellow attendees to share scientific insights on bispecific and T-cell engager discovery, development and manufacturing, ahead of the main conference days, as well as with global service providers and those working in the ADC and TPD fields.
Streamlining CMC & Bioanalysis for Bispecific ADCs to Overcome Added Complexity of Different Components & Prevent Downstream Errors
11:30 am Understanding How CMC Processes Differ for Bispecific ADCs & How to Adapt to Them to Reduce Manufacturing Complexity
- Mapping key CMC differences in bispecific ADCs and traditional ADCs to understand how to adapt manufacturing processes
- Implementing flexible process development and control strategies to prevent downstream challenges
- Leveraging platform technologies to reduce complexity and improve product quality
12:00 pm Learning How to Conduct Bioanalysis for Bispecific ADCs to Accurately Understand the Molecule as a Whole
- Understanding how different components affect the analysis and how that differs from a traditional ADC
- Exploring the differences in bioanalysis from traditional ADCs and how that can be adapted for bispecific ADCs
- Integrating multiple analytical technologies to gain a holistic understanding of pharmacokinetics and stability of the molecule
12:30 pm Lunch
1:30 pm Networking Session
Network with fellow attendees to share scientific insights on bispecific and T-cell engager discovery, development and manufacturing, ahead of the main conference days, as well as with global service providers and those working in the ADC and TPD fields.
Balancing Conjugation Chemistry With Bispecific ADC Design & Optimizing Payload Selection to Enhance Stability & Efficacy
2:15 pm Analyzing the Benefits of Using Cysteine Conjugation vs. Other Conjugation Technologies on Bispecific ADCs & Their Success Rate in Improving Stability of the Molecule
- Evaluating cysteine conjugation vs. lysine, enzymatic and site-specific technologies, and their effect on DAR ratio and uniformity
- Assessing the impact of each conjugation technology on ADC stability
- Exploring how each conjugation technology affects clinical performance
2:45 pm NEOK002 (ABL209): Redesigning an EGFRxMUC1 Bispecific TOP1i ADC With Promising Anti-Tumor Activity & Enhanced Therapeutic Window
- Introducing the development strategy of NEOK002 and discuss what differentiates it from existing EGFR/MUC1 targeting agents
- Exploring the pharmacological and toxicological characteristics of the differentiated features
- Discussing the clinical development potential secured through various preclinical studies
3:15 pm Beyond Bispecific ADCs & The Next Wave: From Better Delivery to Checkmate Killing
- Exploring the evolution from traditional to bispecific ADCs
- Discussing the internalization-lethality gap and defining the biological ceiling of efficacy
- Predicting the next wave focused on overcoming resistance
3:45 pm Networking Session
Final chance to network with fellow attendees ahead of the main conference days.